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Glutamate excitotoxicity plays an important role in neuronal death after ischemia.
However, all clinical trials using glutamate receptor inhibitors have failed. This may be
related to the evidence that activation of different subunit of NMDA receptor will induce
different effects. Many studies have shown that activation of the intrasynaptic NR2A
subunit will stimulate survival signaling pathways, whereas upregulation of extrasynaptic
NR2B will trigger apoptotic pathways. A Lycium barbarum polysaccharide (LBP)
is a mixed compound extracted from Lycium barbarum fruit. Recent studies have
shown that LBP protects neurons against ischemic injury by anti-oxidative effects.
Here we first reported that the effect of LBP against ischemic injury can be achieved
by regulating NR2B and NR2A signaling pathways. By in vivo study, we found LBP
substantially reduced CA1 neurons from death after transient global ischemia and
ameliorated memory deficit in ischemic rats. By in vitro study, we further confirmed
that LBP increased the viability of primary cultured cortical neurons when exposed to
oxygen-glucose deprivation (OGD) for 4 h. Importantly, we found that LBP antagonized
increase in expression of major proteins in the NR2B signal pathway including NR2B,
nNOS, Bcl-2-associated death promoter (BAD), cytochrome C (cytC) and cleaved
caspase-3, and also reduced ROS level, calcium influx and mitochondrial permeability
after 4 h OGD. In addition, LBP prevented the downregulation in the expression of
NR2A, pAkt and pCREB, which are important cell survival pathway components.
Furthermore, LBP attenuated the effects of a NR2B co-agonist and NR2A inhibitor on
cell mortality under OGD conditions. Taken together, our results demonstrated that
LBP is neuroprotective against ischemic injury by its dual roles in activation of NR2A and
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 September 2017 | Volume 11 | Article 288
Shi et al. Neuroprotective Mechanism of LBP Against Ischemia
inhibition of NR2B signaling pathways, which suggests that LBP may be a superior
therapeutic candidate for targeting glutamate excitotoxicity for the treatment of ischemic
stroke.
Keywords: ischemia, Lycium barbarum polysaccharides, excitotoxicity, apoptosis, NR2B, NR2A
INTRODUCTION
Glutamate excitotoxicity is a major factor in ischemia-induced
neuronal death (Nishizawa, 2001). Excess release of glutamate
from presynaptic membranes induced by ischemia overactivates
glutamate receptors leading to a series of events including
intracellular calcium overload, excessive ROS production and
mitochondrial stress and finally neuronal death (Benveniste
et al., 1984; Lipton and Rosenberg, 1994). However, based on
accumulating evidence in the literature, all clinical trials using
glutamate receptor inhibitors have failed (Koh and Choi, 1991;
Morris et al., 1999; Albers et al., 2001; Ikonomidou and Turski,
2002) although some of the inhibitors reduced ischemic damage
in animal experiments (Lin et al., 1993; Reyes et al., 1998; Cai,
2006). It is known that glutamate receptors play important roles
in maintaining physiological functions such as excitatory signal
transduction, learning and memory (Mayer and Westbrook,
1987; Newcomer et al., 2000). Therefore, a more promising
strategy for treating ischemic stroke may be through selectively
blocking excitotoxicity while preserving important physiological
aspects of glutamate receptor subunit function (Cho et al., 2010).
Previous studies have identified three NMDAR subunits:
NR1, NR2 (A–D) and NR3 (A,B). Functional NMDARs
are heterotetramers composed of two glycine–biding
NR1 subunits and two glutamate-binding NR2 subunits,
whereas NR1/NR3 heterotetramers can be combined by glycine
(Chatterton et al., 2002; Mayer and Armstrong, 2004; Paoletti,
2011). Different NR2-containing receptors (NR1/NR2A, or
NR1/NR2B heterotetramers) exhibit different biophysical and
pharmacological properties (Cull-Candy and Leszkiewicz,
2004; Furukawa et al., 2005; Chen and Wyllie, 2006). NR2A
subunits are primarily located at intrasynaptic sites, whereas
NR2B subunits are predominantly located at extrasynaptic sites
(Stocca and Vicini, 1998; Rumbaugh and Vicini, 1999; Tovar
and Westbrook, 1999; Traynelis et al., 2010). Functionally,
NR2A subunits play a neuroprotective role by activating
cellular CREB or Akt pathways (Hardingham and Bading,
2010; Luo et al., 2011; Lai et al., 2014). Activation of NR2A
will induce phosphorylation of CREB which is associated with
BDNF expression and contributes to neuronal survival (Chen
et al., 2008). It has been reported that some drugs may be
neuroprotective against ischemia via enhancing CREB activity
(Raval et al., 2009; Zhang et al., 2010). Conversely, activation of
the extrasynaptic NR2B subunit will trigger apoptotic pathways
by increasing ROS levels and prohibiting CREB expression
(Léveillé et al., 2008; Hardingham and Bading, 2010; Gladding
and Raymond, 2011). When animals experience ischemic insult,
nNOS will translocate to the cell membrane to form the NR2B-
PSD95-nNOS complex that activates nNOS to produce more NO
and causes severe neuronal injury. Some agents have recently
been tested in the rat MCAOmodel and stroke primates showing
that disruption of nNOS-PSD95 or NR2B-PSD95 interaction
reduced infarct area in ischemic models (Zhou et al., 2010;
Cook et al., 2012). Whether both NR2A and NR2B subunits
could be simultaneously regulated to achieve neuroprotection by
pharmacological drugs remains unknown.
Lycium barbarum (Gouqi or wolfberry) is well known as
a traditional Chinese medicine and healthy food supplement
in China and other countries (Amagase et al., 2009). Lycium
barbarum polysaccharide (LBP) is a mixed compound extracted
from the fruits of Guoqi, composing primarily of rhamnose,
arabinose, xylose, galactose, mannose and galacturonic acid (Zou
et al., 2010). Recent years, many studies have investigated LBP’s
structures, bioactive components and degradation. Studies have
found that the water-soluble LBP containing 3.75% proteins has
a β-D-(1 → 6)-galactan as a backbone with highly branched
polysaccharide (Wang Z. et al., 2014; Yuan et al., 2016). A
new study reported that a p-LBP was isolated and purified
from LBP-and p-LBP was a homogeneous heteropolysaccharide
as a pectin molecule with an average molecular weight of
64 kDa, approximately 87 nm hollow sphere in 0.05 mol/L
sodium sulfate solution (Liu et al., 2016). Many studies have
shown that LBP has strong anti-oxidative effects in diverse
injury types, including doxorubicin-induced cardiotoxicity (Xin
et al., 2011) and oxidative liver injury (Wu et al., 2010; Xiao
et al., 2012). In addition, some studies showed that LBP plays
beneficial roles in aging (Tang and He, 2013), hypoglycemia
(Zhu et al., 2013) and anti-radiation or chemotherapy damages
(Gong et al., 2005). Concerning nervous system damage, LBP
protected ganglion cells against acute ocular hypertension (Mi
et al., 2012), partial optic transection injuries (Li et al., 2013) and
retinal ischemia/reperfusion injury (Li et al., 2011). Furthermore,
LBP can prevent cortical neurons from damage against ischemic
insults through anti-oxidative and anti-apoptotic mechanisms
(Rui et al., 2012; Wang T. et al., 2014).
LBP appears to have broad benefits in a variety of injury
types by regulating different pathways. Based on the idea that
different NMDA receptor subunits have distinct functions,
we hypothesized that LBP exhibits its neuroprotective effect
against ischemic injury by regulating NR2A and NR2B signaling
pathways. The present study investigated the underlying
mechanisms of LBP-induced neuroprotection in in vivo ischemia
and in vitro oxygen-glucose deprivation (OGD) models and
unraveled that indeed both NR2A and NR2B receptor signaling
pathways play crucial role in the actions of LBP.
MATERIALS AND METHODS
Animals and Groups
Adult male Wister rats (220–300 g) were obtained from the
Animal Experiment Center of Southern Medical University
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(Guangzhou, China). Animals were housed and cared for in
accordance with the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All experimental
protocols involving rats were approved by the ethical committee
of Jinan University and were carried out in accordance with
approved guidelines and regulations. All efforts were made to
minimize the number of animals used and their suffering.
Animals were randomly assigned to five groups (n = 10 per
group): a sham group, vehicle group (fed PBS for 1 week before
and after four-vessel occlusion (4-VO) ischemia), Pre-LBP group
(fed LBP for 1 week before ischemia followed by feeding PBS for
1 week), the Post-LBP group (fed PBS for 1 week before ischemia
followed by feeding with LBP for 1 week), and LBP-LBP group
(fed LBP for 1 week before and after ischemia).
Administration of LBP In Vivo
LBP was purified from Lycium barbarum, which was harvested
in Ningxia province of China. The preparation for LBP extracts
was performed as reported previously (Yu et al., 2005). LBP was
dissolved in PBS at dose of 4 mg/mL according to previous study
(Li et al., 2013). LBP (20 mg/kg body weight) was administrated
intragastrically with an oral gavage needle to the rats according
to methods used in previous research (Wang T. et al., 2014).
Standard chow diet and tap water were freely available to all rats.
Transient Global Ischemia
Transient global ischemia was induced by using the 4-VO
method with minor modifications (Pulsinelli et al., 1982; Han
et al., 2016). Briefly, rats were anesthetized by intraperitoneal
(i.p.) injection of 400 mg/kg chloral hydrate (Fluka, Buchs,
Switzerland). Body temperature was maintained at 37.0 ± 0.2◦C
during surgery using heating pads. The bilateral vertebral
arteries were exposed and permanently electrocauterized. Both
common carotid arteries (CCAs) were occluded with carotid
artery clips for 15 min, and blood flow was monitored at a
point in the skull (bregma: −2.0 mm, midline: 5.0 mm) with a
probe connecting a laser-Doppler flowmetry device (MoorVMS-
LDF2, Moor Instruments, Devon, UK) before, during and after
ischemia. The ischemic model was considered successful when
the cerebral blood flow decreased to 10%–15% of pre-ischemic
levels and returned to the baseline (100 ± 10%) after release
of the carotid artery clips. Sham animals underwent all aspects
of handling and surgery without occlusion of the vertebral and
CCAs.
Morris Water Maze
One week after reperfusion, the mice were trained to perform
in the Morris water maze navigation task. A circular pool
(1.2 m diameter and 50 cm depth) was filled with water
(maintained at 23 ± 2◦C). A 10-cm platform was placed 1.5 cm
underneath the water surface (to hide its visibility) in one
quadrant of the pool. The navigation task was performed in
the present study as previously described (Jing et al., 2015).
Briefly, rats were first adapted to swimming for 2 min the
day before testing. Over the following four consecutive days,
rats underwent learning trials to escape water by finding the
invisible platform. The maximum time for each rat to swim
in the pool was 60 s. If the animal did not find the platform
within 60 s, the rat was gently guided to the platform and
left on it for 15 s. Each rat underwent four trials at four
starting positions in four quadrants each day with an interval
of 15 s. The platform was removed on the fifth day, and
the rats were allowed to navigate in the pool for 60 s. The
escape latency to find the platform in the first 4 days and the
duration of swimming in the platform quadrant at the fifth day
were recorded. All trial information was collected automatically
by a video camera linked to an animal behavioral recording
system (Ethovison XT, Noldus Information Technology Co,
Netherland).
Tissue Preparation for Hematoxylin-Eosin
(HE) Staining
The day after finishing behavior assessment, the rats were
anesthetized with 10% chloral hydrate (400 mg/kg, i.p) and then
transcardially perfused with 0.9% NaCl solution followed by 4%
paraformaldehyde in 0.1M phosphate buffer (PB, pH 7.4). Brains
were removed and post-fixed in the same fixative at 4◦C for
24 h. Brain blocks containing the hippocampus were processed
for dehydration with an increasing alcohol gradient and three
xylene clearing steps with an Automated Tissue Processor
(LYNX II, Hatfield, PA, USA). The blocks were embedded
with paraffin in an embedding machine (Thermo Scientific
HistoStar, Kalamazoo, MI, USA) and sectioned at 10 µm
thickness with a paraffin microtome (Leica, RM2235, Wetzelar,
Germany). Sections were mounted on slides for Hematoxylin-
Eosin (HE) staining by two individuals blinded to the treatment
groups.
Quantitative Analysis of Hippocampal
CA1 Neuron Damage
At least five animals in each group were assessed for neuronal
injury. Six to nine sections with typical hippocampal
structures in each animal were photographed under a
microscope (Leica, CTR 6000) using 10× objective with
10× eyepiece field. The degree of neuronal damage in
the CA1 area was evaluated based on extent of neuron
death (Pulsinelli and Brierley, 1979); level 0 (no damage),
level 0.5 (<10%), level 1.0 (10%–30%, mild damage),
level 1.5 (30%–50%, mild-to-moderate damage), level 2.0
(50%–70%, moderate damage), level 2.5 (70%–90%, moderate-
to-severe damage) and level 3.0 (>90%, severe damage).
The original quantitative data was analyzed with StatView
5.1 software. Differences were considered significant when
p< 0.05.
Primary Cortical Neuron Culture
For primary cortical culture, female Wistar rats (provided by
Jinan University animal center) were anesthetized with chloral
hydrate (400 mg/kg) at E18 gestation, and embryos extracted
from the uterus. The brains of embryos were removed and
placed into separate dishes. Next, the cortices were dissected
and cut into pieces, followed by digestion with 0.125% trypsin
(w/v, Gibco, USA) at 37◦C for 30 min. Digestion was stopped
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by 10% FBS (Gibco). After suspension, centrifugation and
filtration, cells were re-suspended in Neurobasal media (Gibco)
containing 2% B27 (Gibco), 2 mM glutamine (Gibco), 1 mM
sodium pyruvate, 25 µM glutamate, 100 U/ml penicillin
and 100 µg/ml streptomycin (Gibco). The cells were then
plated on multiwell plates or dishes (Corning, USA) coated
with 0.01% (w/v) poly-L-lysine (Sigma, USA) at a density
of 105 cells/cm2 and placed in a standard incubator (Heal
Force, China) maintained at 37◦C in 95% air-5% CO2. For
immunohistochemical detection and fluorescent staining, cells
were plated on coverslips in 24-well plates or in dishes in
the same density. Half of the medium was changed every
3 days.
OGD and Reperfusion
After cells were cultured in wells or dishes for 2 weeks, the
culture medium was removed and the cells washed three times
with deoxygenated (bubbled with N2 to remove the residual
O2 for 30 min) and glucose-free BSS (consisting of 116 NaCl,
5.4 KCl, 0.8 MgSO4, 1.0 NaH2PO4, 26.2 NaHCO3, 1.8 CaCl2, all
in mM). Then, the wells or dishes were placed in an anaerobic
chamber (Coy Laboratory, USA) with 5% CO2-95% N2 at 37◦C
for a designated period of OGD. OGD was terminated by
replacement of normal culture medium. Cells were placed back
in a standard incubator for 24 h before being analyzed. A control
group was cultured with normal culture medium in the standard
incubator.
In Vitro Drug Administration
LBP was dissolved in DDW at a concentration of 100 mg/ml
to prepare a stock solution, and the LBP working solution was
diluted to 100 mg/l based on a previous study (Ho et al., 2009).
D-serine (S4250, Sigma) was first dissolved in DDW as stock
solution (200 mM). A stock solution of NVP-AAM077 (P1999,
Sigma) was prepared in DMSO (100 µM). Based on other
studies (Martin et al., 2003; Tovar et al., 2013), the working
concentration of D-serine was 200 µM and NVP-AAM077 was
100 nM.
Detection of Neural Viability and Mortality
Neural viability was measured using a MTT reduction kit
(Sigma, USA). Briefly, primary cultured neurons were exposed
to designated periods of OGD. Twenty-four hours after the
reperfusion, neurons were incubated with 500 µg/ml MTT
in culture medium at 37◦C for 4 h. Next, the medium
was removed, and 100 µL DMSO was added into each
well of 96 well multiplates to dissolve the crystals. The
absorbance at 550 nm was measured with a microplate reader
(PerkinElmer, USA). Neural death was determined by measuring
the concentration of LDH released from the damaged cells
with a LDH assay kit (Dojindo, Japan) following manufacturer’s
instruction.
Western Blot Analysis
Cells cultured in dishes were lysed in ice-cold lysis buffer
with appropriate protease inhibitors (Roche, USA). Lysed
cells in lysis buffer were centrifuged (14,800 rpm, 20 min,
4◦C) and supernatant was collected. The supernatant protein
concentration was determined using a bicinchoninic acid
(BCA) protein assay kit (Pierce, USA) at an absorbance at
562 nm in a microplate reader (PerkinElmer, USA). Protein
concentration was then calculated according to the standard
curve. Equivalent amounts of protein (40 µg) were separated
by sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-
PAGE) using 8%–12% Bis–Tris gels (Beyotime, China). Proteins
initially ran through a stacking gel for 30 min at 90 V using an
electrophorator (Bio-Rad, USA), and then through a separating
gel at 120 V for 60–90 min. Then the proteins were then
transferred onto PVDF membranes with a constant current of
250 mA for 60 min. Following a blocking step (0.1% Tween-
20, 5% nonfat milk in 0.1% TBS for 1 h, RT), the PVDF
membranes were incubated with primary antibodies overnight at
4◦C with gentle shaking. The primary antibodies and dilutions
used were as follows: nNOS, PSD95, cytC, Bcl-2-associated
death promoter (BAD) and GAPDH (1:1000, Abcam, UK);
pCREB (Ser133), pAkt (Ser-473) and cleaved caspase-3 (1:1000,
Cell Signaling Technology, USA); NR2Aand NR2B (1:1000,
Millipore, USA). All antibody dilutions were made using 0.1%
TBST with 5% BSA. After three 10 min washes, the membranes
were then incubated with HRP conjugated anti-rabbit IgG or
anti-mouse IgG (1:1000, Abcam, UK) followed by incubation
with ECL reagent (WBKLS001000, Millipore, USA) for 5 min,
and detected with an imaging system (Alliance 6.7, UVITEC
Limited, UK).
Immunofluorescence Staining
Cells cultured on coverslips were fixed with 4%
paraformaldehyde for 10 min at room temperature. After
three washes with 0.01 M PBS, non-specific proteins were
blocked with a blocking buffer containing 5% (v/v) normal
goat serum (Sigma), 3% (w/v) BSA (Sigma) and 0.05% (v/v)
Triton X-100 (Sigma) in PBS at RT for 30 min. Next, the
cells on coverslips were incubated with primary antibodies
(MAP2, 1:1000, Millipore or GFAP, 1:3000, Millipore)
overnight at 4◦C. Following three rinses with PBS, the
coverslips were incubated with an appropriate fluorescence-
conjugated secondary antibody (1:1000, Jackson, USA) at RT
for 1 h followed by three rinses. Finally, the coverslips were
mounted with Antifade Mounting Medium (Vector, USA)
with or without dihydrochloride (DAPI, 1:1000, Sigma, USA).
Images were acquired with a fluorescence microscope (Leica,
Germany).
Fluoro JADE B Staining
Neural damage was identified using Fluoro JADE B (FJB, Sigma,
USA) following a protocol modified from the manufacturer’s
instructions. Briefly, cells cultured on coverslips were immersed
in 80% ethanol containing 1% NaOH for 2 mins, and then
immersed in 70% ethanol followed by a 1 min rinse with doubly
distilled H2O (DDW). Next, the cells were treated with 0.06%
KMnO4 at RT (shaking) for 15 min. After a 1 min rinse with
DDW, the cells were incubated with FJB (0.0004%) for 5 min and
then rinsed three times with DDW. The coverslips were mounted
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with 80% glycerin. Photos showing FJB labeling were taken with
a fluorescence microscope (Leica, Germany).
Fluorescent Staining for Measurement of
Intracellular Calcium, ROS and
Mitochondrial Permeability in Living Cells
Primary cortical neurons were cultured on coverslips in petri
dishes. After different experimental processes, the following
assessments were performed.
Measurement of Intracellular Calcium
Cells were washed with Hank’s solution three times then
incubated with 10µMFluo-4/AM (Dojindo, Japan) for 30 min at
37◦C in the dark followed by three washes with Hank’s solution.
Measurement of ROS Level
Intracellular ROS was detected by a molecular probe (CellROX
Green reagent, Life Technologies, Camarillo, CA, USA). Briefly,
cells were incubated with the reagent (5 µM) for 30 min followed
by three washes with PBS.
Detection of Mitochondrial Permeability
Cells were incubated with rhodamine123 (1 µM) for 10 min, and
then rinsed three times with PBS. Following the last rinse, PBS
was replaced by culture medium.
Photos showing the density of intracellular calcium, ROS
level and mitochondrial permeability of living cells were taken
by a fluorescence microscope (Zeiss, Axio, Germany). The
fluorescence intensity in images was analyzed by ImageJ software
(NIH).
Quantification
For all in vitro quantitative analyses, three to five experiments
were performed. The mean values for MTT and LDH assays
were measured from three wells in each group in each cell
culture. The final value was determined by comparison of the
value of LDH or MTT to that of control group (as 100%). For
immunofluorescence quantification, 8–10 photos were randomly
taken from four to five coverslips in each group by a fluorescence
microscope under a 20× objective in each experiment. Two
blinded individuals counted the number of MAP2 or GFAP
positive cells. Similar processes of quantitative analysis were
performed for FJB, intracellular calcium, ROS andmitochondrial
permeability. Fluorescent intensity was measured using ImageJ
software (version 1.45 s, NIH, USA). For quantitative protein
analysis from Western blotting, photos were obtained with an
imaging system (Alliance 6.7, UVITEC Limited, UK). Signal
intensities of the membranes were analyzed using Quantity One
software (Bio-Rad).
Statistics
All results were expressed as mean ± SEM. All original data
were input to StatView (Version 5.0.1) and a one-way analysis
of variance (ANOVA) was performed for multiple comparisons
followed by post hoc Bonferroni/Dunn test. The difference
for each comparison was considered statistically significant at
p< 0.05.
FIGURE 1 | Hematoxylin-Eosin (HE) staining showing effects of Lycium
barbarum polysaccharide (LBP) treatment on neuronal survival in the
CA1 area. Morphological changes of neurons in different treatment groups are
shown in representative pictures (A–E). Sham group, without four-vessel
occlusion (4-VO) injury; Vehicle group, 4-VO insult only; Pre-LBP group,
pretreated with LBP for 1 week before 4-VO; Post-LBP, 4-VO followed by LBP
treatment for 1 week; and LBP-LBP, treatment with LBP for 1 week before
and after 4-VO. Quantitative analysis is shown in (F) (n = 5. ∗∗P < 0.01).
RESULTS
LBP Reduced Neuronal Damage and
Attenuated Memory Deficits after Global
Ischemia In Vivo
To test whether LBP is neuroprotective following transient
global ischemia in vivo, we intragastrically fed rats with LBP
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for 1 week before or after ischemia, or both. After HE
staining of coronal brain sections including the hippocampus,
we evaluated the degree of neuronal damage in the CA1 area
(damage score from 0 to 3) based on previously established
criteria with modification (Pulsinelli and Brierley, 1979). The
results showed that approximate 90% of neurons died in the
CA1 area in the vehicle group (damage score = 2.4 ± 0.1) at
14 days after ischemia (Figures 1B,F) compared to the sham
group (Figures 1A,F; p < 0.01). However, with LBP treatment,
CA1 neuron morphology improved compared to the vehicle
treated group (Figures 1C–E), and the degree of damage of
CA1 neurons was significantly reduced in the Pre-LBP, Post-LBP
and LBP-LBP groups (damage score =1.3 ± 0.1, 1.1 ± 0.2 and
1.1± 0.1 respectively, all p< 0.01 vs. vehicle group; Figure 1F).
Next we examined the effects of LBP on ischemia-induced
memory impairment. Rats received 4 days’ swimming training
in Morris water maze from which the escape latency of rats was
recorded. The duration in the platform quadrant and swimming
track was also measured after removing the platform on the
fifth day. As shown in Figure 2A, all groups showed a trend of
decreasing escape time with extended training. However, when
comparing the mean time during the first 4 days of training
period, the vehicle group (31.2 s ± 2.97) took longer time than
the sham (15.08 s ± 1.86), Pre-LBP (18.72 s ± 3.38), Post-LBP
(19.31 s ± 3.77) and LBP-LBP (16.38 s ± 2.38) groups (all,
p < 0.05, Figure 2A). For swimming duration in the platform
quadrant at day 5 when the platform was removed, the LBP-LBP
group (22.1 s ± 1.8) swam significantly longer than the vehicle
group (15.6 s ± 2.5, p < 0.05, Figure 2B), and performed
similarly to the sham group (21.8 s ± 1.7, p > 0.05, Figure 2B).
Figure 2C illustrates the rats’ movement track at day 5, from
which more track lines in the platform quadrant were found in
the sham, Pre-LBP, Post- LBP and LBP-LBP groups but less in
the vehicle group.
LBP Enhanced the Viability of Cortical
Neurons Exposed to OGD 4 h In Vitro
We carried out in vitro experiments to reveal mechanisms of
neuroprotection of LBP underlying OGD. Based on findings
that there is heterogeneity of hippocampal neurons in response
to ischemia such as highly vulnerable CA1 neurons and
resistant CA3 neurons, and cortical neurons in the frontal
and parietal cortex are more evenly vulnerable to ischemia
(Pulsinelli et al., 1982) we cultured cortical cells for 7 days
and identified neurons (MAP2) and astrocytes (GFAP) using
immunofluorescent staining. Approximately 95% of cells were
neurons and 5% astrocytes (Figure 3A). Next, we investigated
the relationship between OGD duration (from 1 h to 12 h)
and neuronal death. Our results showed that 20% of neurons
died when exposed to OGD for 1 h, whereas 50% of neurons
were lost after 4 h OGD (Figure 3B). We then detected the
protective effect of LBP on cultured neurons exposed to 4 h
OGD. Figure 3C shows the effects of LBP on cortical neuron
morphological changes. OGD caused neuronal dendrites to
become varicose (Figure 3C3, arrows). However, LBP treatment
prevented dendritic degeneration (Figure 3C4) and smooth
dendrites were found similar to that of control (Figure 3C1) or
control + LBP (Figure 3C2) groups. In addition, we detected
neural injury with FJB staining (Schmued and Hopkins, 2000).
When exposed to OGD for 4 h, strong FJB staining was
evident in injured neurons (Figure 3D3, arrow). However,
these injury signals were diminished in OGD+LBP neurons
(Figure 3D4) with similar weak staining to that observed in
control or control + LBP groups (Figures 3D1,D2). Quantitative
analysis showed that the density of FJB positive cells increased
to 205.2% ± 10.1 after 4 h exposure to OGD (P < 0.01 vs.
control and Con-LBP groups, Figure 3E). However, value
dropped to normal levels (107.9 ± 4.9%, P < 0.01 vs. OGD
but P > 0.05 vs. control and Con-LBP groups) with LBP
treatment. Consistent with FJB detection, neuron mortality
significantly increased to 168.9% ± 2.3 after 4 h exposure to
OGD (P < 0.01 vs. control and Con-LBP groups, Figure 3E),
whereas it decreased to 137.4% ± 4.0 after the administration
of LBP (P < 0.01 vs. OGD group). Furthermore, cell viability
reduced to 54.2% ± 4.3 in the 4 h OGD group (P < 0.01,
vs. control and Con-LBP groups, Figure 3E) but increased
to 90.2% ± 9.6 after LBP treatment (P < 0.01, vs. OGD
group).
Neuroprotective Effects of LBP Was
Mediated by Blocking NR2B Signaling
Pathway
After confirming the neuroprotective effects of LBP in vitro,
we next investigated whether LBP exhibited neuroprotection by
blocking NR2B signaling pathway. We detected major proteins
in the NR2B signaling pathway. First, we studied the expressions
of NR2B, PSD95 and nNOS in different durations of OGD.
We found that NR2B expression dramatically increased to
approximate twice that of the control level after exposure to
OGD from 30 min to 2 h, followed by a marked decrease to
16% ± 4 and 14% ± 2 after 4 h and 8 h OGD duration (all
P < 0.01 vs. control, Figure 4A). Expression of PSD95 did not
show obvious changes with different OGD durations ranging
from 15 min to 8 h (p > 0.05 vs. control), however, nNOS
expression gradually increased as OGD duration increased from
15 min to 8 h (all P < 0.05 or P < 0.01 vs. control; Figure 4A).
Based on these results, we targetedmild injury (OGD for 1 h) and
severe injury (OGD for 4 h) to test how LBP affected these protein
expressions. With 1 h exposure to OGD, LBP antagonized the
increased expression of NR2B from 256% ± 12 to 129% ± 5 and
nNOS from 168% ± 2 to 119% ± 9 (both P < 0.01 vs.
OGD group, Figure 4B). However, LBP did not affect the
expression of PSD95 at this time point. With 4 h exposure
to OGD and expression of NR2B dropped to 59% ± 4, LBP
did not significantly alter the expression of NR2B (56% ± 4;
Figure 4C). Likewise, LBP did not alter PSD95 expression at
this time point (P > 0.05 vs. control). However, LBP markedly
reversed the increase in nNOS expression from 208.7% ± 4 to
control levels (119.0% ± 8, P < 0.01 vs. OGD group and
P > 0.05 vs. control). We further found that ROS level
significantly increased to 302.1% ± 13.5 (P < 0.01 vs. control)
in neurons exposed to OGD for 4 h, and this increase was
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FIGURE 2 | Behavioral analysis in the Morris water maze showing the effects of LBP on ischemia-induced spatial memory deficits. (A) Escape latency of rats in
different groups during the 4 days’ swimming training. (B) Duration in the platform quadrant on the fifth day after the platform was removed. (C) Swimming track of
rats in different group on the fifth day (∗P < 0.05; n = 10).
blocked by LBP (131.7% ± 11.2, p < 0.01 vs. OGD only,
Figure 4D).
It has been reported that nNOS mediates mitochondrial
injury (Yao et al., 2012) and subsequently initiates the
pro-apoptotic caspase cascade via BAD (Adachi and Imai, 2002),
cytochrome C (cytC) and excessive Ca2+ influx (Helmreich,
2001; Ito et al., 2013). Therefore, we further investigated
whether LBP reduced mitochondria injury and apoptosis.
Our results showed that 1 h OGD did not significantly
influence expression of Bad, cytC or cleaved caspase-3,
and LBP also had no obvious effects on the expression
of these proteins (Figure 5A). However, when exposed to
OGD for 4 h, the protein level of Bad, cytC and cleaved
caspase-3 in neurons increased to 215% ± 7, 196% ± 4 and
251% ± 6 respectively (p < 0.01 vs. control, Figure 5B).
In addition, LBP significantly reduced Bad, cytC and cleaved
caspase-3 expression to 112% ± 13 or 102% ± 2, or 146% ± 5
(all p < 0.01 vs. OGD group; Figure 5B). The intracellular
concentration of calcium (measured by fluo-4) of cortical
neurons increased approximate 4-fold (385% ± 14) at 24 h
after exposure to OGD for 4 h (p < 0.01 vs. control,
Figure 5C). However, LBP dramatically reduced this value
to 175% ± 4 (p < 0.01 vs. OGD 4 h). The mitochondrial
permeability (detected by Rhodamine123) increased to twice
that of controls (199.5% ± 3; p < 0.01 vs. control, Figure 5D).
However, LBP notably reduced the signal density to 109% ± 6
(p < 0.01 vs. OGD 4 h), similar to control level (p > 0.05 vs.
control).
Neuroprotective Effects of LBP Was also
Mediated by Activating NR2A-Akt-CREB
Pathways
Next, we investigated whether LBP-induced neuroprotection
against OGD was also mediated by the NR2A-Akt-CREB
pathway. Our findings demonstrated NR2A expression was
maintained at normal levels with 2 h of OGD exposure before
it decreased to 66.5 ± 11.4% at 4 h OGD and 33.5 ± 2.8% at
8 h OGD, respectively (both p < 0.01 vs. control, Figure 6A).
Expression of pAkt dramatically decreased fromOGD for 30min
to OGD for 8 h (59.5% ± 7.1, 55.9% ± 7.1, 57.5% ± 9.6,
53.6% ± 4.6 and 52.9% ± 8.4, respectively; all p < 0.01 vs.
control). Expression of pCREB remained unchanged with 1 h
OGD, but dramatically decreased to 50.8% ± 4.6 at 2 h OGD,
46.2% ± 7.4 at 4 h OGD and 32.1% ± 6.6 at 8 h OGD (all
p < 0.01 vs. control). We further investigated the effects of LBP
on the expression of major proteins related NR2A signaling. At
1 h OGD exposure, we observed no differences in expression of
NR2A, pAkt or pCREB between the OGD group and OGD+LBP
group (p > 0.05, Figure 6B). However, at 4 h OGD exposure,
LBP significantly reversed the decrease in expression of NR2A
(from 58.6% ± 0.7 to 93.8% ± 2.0), pAkt (from 45.7 ± 2.4% to
85.9 ± 2.9%) and pCREB (from 29.5% ± 3.2 to 88.5% ± 3.4),
respectively (all p < 0.01), when compared with the OGD group
(Figure 6C). LBP upregulated the NR2A and pCREB expression
to the control level (p> 0.05 vs. control), although expression of
pAkt remained lower than the control (p< 0.05 vs. control).
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FIGURE 3 | Effects of LBP on neuronal viability and mortality. (A) Immunochemistry staining showing that the majority of the cultured cells are neurons
(MAP2 positive cells, red) with few astrocytes (GFAP positive cells, green). (B) Two slopes showing the relationship between neuronal viability (red slope), death (blue
slope) and oxygen-glucose deprivation (OGD) duration. (C) Immunochemistry staining showing effects of LBP treatment on morphological changes of neurons
exposed to 4 h OGD. Neurons exhibited features of beaded dendrites in the OGD group (C3, arrows). However, LBP recovered normal dendritic morphology (C4,
arrow). (D) Fluoro JADE B (FJB) staining (injury marker) showing strong fluorescent labeling in most neurons when exposed to OGD for 4 h (D3, arrows). However,
LBP treatment reduced the staining intensity (D4, arrow). (E) Quantitative results showing effects of LBP treatment on neuronal injury (FJB staining), mortality and
viability when exposed to 4 h OGD (∗∗P < 0.01). The scale bar in (D4) is equal to (C1–C4) and (D1–D3).
LBP Diminished the Effects of NR2A
Antagonist and NR2B Co-Agonist during
OGD
To further confirm that LBP-induced neuroprotection was
mediated by inhibiting NR2B signaling or activating the
NR2A signaling pathway, we employed a NR2B co-agonist
(D-serine) and a NR2A antagonist (NVP-AAM077) in
this study. Our results showed that 4 h OGD caused
twice the neuronal mortality (205.1% ± 12.6, p < 0.01 vs.
control; Figure 7A). This mortality was further enhanced by
administration of D-serine (259.1% ± 14.6) or NVP-AAM077
(264.5% ± 10.6; all p < 0.05 vs. OGD alone). LBP treatment
markedly blocked the increased cell mortality caused by
D-serine or NVP-AAM077 and reduced neural death to
140.8% ± 2.3 in the LBP+D-serine group or 156.4% ± 4.5 in
the LBP+NVP-AAM077 group (p < 0.01 vs. D-serine or
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FIGURE 4 | Effects of LBP on the expression of NR2B, PSD95, nNOS and production of ROS after exposed to 1 h or 4 h OGD. (A) Expression of NR2B, PSD95 and
nNOS by neurons in response to different durations of OGD. (B) Administration of LBP blocked the increase in expression of NR2B and nNOS when neurons were
exposed to OGD for 1 h. (C) LBP application antagonized the increase in nNOS expression, but did not further inhibit NR2B when NR2B level was reduced after 4 h
OGD. (D) LBP application blocked the increase in ROS production 4 h OGD exposure (∗P < 0.05; ∗∗P < 0.01; ##P < 0.01).
NVP-AAM077 group, respectively). Consistent with the
observed neuron death results, cell viability decreased to
45.9% ± 9.7 in the OGD group (Figure 7B), which was
further reduced by application of D-serine (38.8% ± 1.3)
or NVP-AAM077 (38.6% ± 2.4). However, LBP treatment
considerably prohibited reduced neuronal viability induced by
D-serine or NVP-AAM077 and increased neural viability to
67.4% ± 1.5 in the LBP+D-serine group and 65.7% ± 2.6 in
the LBP+NVP-AAM077 group (p < 0.01 vs. D-serine or
NVP-AAM077 group, respectively). These results indicated
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FIGURE 5 | Effects of LBP on expression of Bcl-2-associated death promoter (BAD), cytochrome C (cytC) and cleaved caspase-3, and intracellular calcium and
mitochondrial permeability after 4 h OGD exposure. (A) LBP did not affect expression of Bad, cytC, or cleaved caspase-3 when these neuronal protein levels
stabilized after 1 h OGD. However, in response to 4 h OGD, application of LBP significantly blocked the increase in expression of Bad, cytC and cleaved caspase-3
(B), antagonized the enhancement in intracellular calcium (Fluo-4) (C), and reduced mitochondrial permeability that was detected by Rhodamine 123 (Rohd 123, D;
∗P < 0.05; ∗∗P < 0.01; ##P < 0.01).
that LBP’s neuroprotection was mediated by its dual roles in
blocking NR2B signaling and activating NR2A signaling. To
further confirm this conclusion, we determined the effects of
D-serine or NVP-AAM077 on expression of nNOS (a major
protein of NR2B signaling pathway) and pAkt (a major protein
of NR2A signaling pathway). As shown in Figures 7C,D,
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FIGURE 6 | Effects of LBP on the expression of NR2A, pAkt and pCREB proteins after exposed 4 h OGD. (A) Expression of these proteins at different OGD
duration. (B) When exposed to OGD for 1 h, LBP did not influence expression of NR2A, pAkt and pCREB proteins. However, LBP treatment markedly inhibited the
decrease in these protein levels after neurons were exposed to 4 h OGD (C; ∗P < 0.05; ∗∗P < 0.01).
the nNOS expression increased to 174.0% ± 15.2 after 4 h
OGD exposure, and this expression was further enhanced to
280.3 ± 11.9% in the presence of D-serine (p < 0.01 between
OGD alone group and D-serine group). However, LBP
treatment dramatically blocked the expression of nNOS to
122.5% ± 9.0 (p < 0.01 vs. D-serine group). LBP+NVP-
AAM077 group invariably showed a slight reduction of
nNOS expression compared with NVP-AAM007 alone group,
although not statistically significant. These results suggest
that LBP reduced expression of nNOS through inhibiting
NR2B signaling pathway. Furthermore, pAkt expression
significantly decreased in response to OGD alone (75.3% ± 1.4,
p < 0.01 vs. control), which was further downregulated with
administration of NVP-AAM077 to 46.4% ± 3.3 (p < 0.01 vs.
OGD alone group). However, LBP reduced the inhibition of
NVP-AAM077 and increased pAkt expression to 58.8% ± 3
(p < 0.05, compared between NVP-AAM077 group and LBP-
NVP-AAM077 group). There was no significant difference
of pAkt expression between D-serine group (64.2% ± 2.3)
and LBP+D-serine group (67.1% ± 4.5, p > 0.05). Taken
together, these results indicated that LBP upregulates expression
of pAkt by stimulating NR2A signaling pathway as well as
downregulates nNOS expression by inhibiting NR2B signaling
pathway after OGD.
DISCUSSION
In the present study, our results demonstrated that LBP
significantly prevented CA1 neuronal damage after transient
global ischemia and reduced cortical neuronal death in response
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FIGURE 7 | Neuroprotective effect of LBP was confirmed by using NR2B agonist D-serine and NR2A antagonist NVP-AAM077. LBP treatment dramatically
antagonized the increase in cellular mortality caused by D-serine and NVP-AAM077 (A) and the decrease in cellular viability in response to 4 h OGD (B).
Furthermore, LBP primarily blocked the increase in expression of nNOS caused by D-serine and inhibited the decrease in expression of pAkt caused by
NVP-AAM077 when cultured neurons were exposed to OGD for 4 h (C,D; ∗P < 0.05; ∗∗P < 0.01).
to OGD in vitro. LBP also ameliorated memory deficits
after ischemia. Here, we provide the first evidence indicating
that the neuroprotection of LBP is mediated by inhibiting
the expression of major proteins in the NR2B signaling
pathway including NR2B, nNOS, Bad, cytC and cleaved
caspase-3, mitochondrial stress and calcium influx (Figure 8).
LBP also prevented the reduction in expression of major
proteins of NR2A signaling pathway including NR2A, pAkt and
pCREB.
Strong evidence has shown that LBP exhibits neuroprotective
effects through anti-oxidative stress pathways or by inhibiting
JNK signaling in different injury models (Li et al., 2013; Xing
et al., 2016). In ischemic models, LBP reduced infarct area and
ameliorated neurological dysfunction in MCAO mice through
anti-apoptotic mechanisms and protection of blood brain barrier
(Yang et al., 2012; Wang T. et al., 2014). Although it has
been reported that LBP can antagonizes glutamate toxicity on
neurons through the JNK pathway (Ho et al., 2009), here we first
reported that LBP exerts its neuroprotective effect by modulating
both NR2A and NR2B expression and their signaling pathways.
The regulation on these two pathways by LBP is not likely to
occur at mild OGD when their protein expression is stable,
but LBP exerts its effect during severe OGD/ischemia which
causes changes in expression of proteins in these pathways.
During mild injury (1 h OGD), expression of PSD95, Bad, cytC
and cleaved caspase-3 in the NR2B signaling pathway did not
change while NR2B and nNOS levels increased. Interestingly,
administration of LBP only reduced expression of NR2B and
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FIGURE 8 | A schematic picture showing the neuroprotective effects of LBP
through inhibiting the NR2B signaling pathway and activating the NR2A
signaling pathway against ischemic/hypoxia injury.
nNOS but did not affect expression of other proteins in the
pathway. It is currently unknown on the underlyingmechanisms.
It will be interesting to further investigate whether LBP regulates
protein turnover of NR2B and nNOS through post-translational
modification or directly regulates transcription of these genes.
Concerning NR2A signaling in response to mild OGD, LBP
application did not modify NR2A and pCREB levels as indicated
by lack of alteration in their expression. As for pAkt expression,
administration of LBP for 1 h under OGD conditions could not
upregulate its expression when it was reduced at this time point.
It has been reported that NMDA induces maximal activation
of Akt phosphorylation at 3 h (Zhu et al., 2002). Therefore, we
speculate that LBP upregulates expression of pAkt by increasing
the protein expression of NR2A. This is supported by our
observation that when exposed to severe injury (4 h OGD), LBP
treatment significantly increased expression of NR2A, pCREB
and pAkt when the expression of these proteins was decreased.
LBP treatment also markedly blocked the increase in expression
of major proteins in the NR2B signaling pathway such as nNOS,
Bad, cytC and c-caspase-3 under 4 hOGD conditions.We cannot
rule out the possibility that LBP can reduce NR2B expression
under this condition. However, when NR2B level has already
been markedly reduced during this period, LBP did not further
inhibit NR2B expression. The reduced expression of NR2B at
4 h and 8 h OGD may be caused by a compensatory mechanism
responding to the increased level of NR2B at early stage of OGD
(1 h). Therefore, the inhibited effect of LBP on NR2B expression
mainly occurred in the early stage of OGD.
It is plausible that in the early stage (1 hOGD), overexpression
of NR2B and nNOS may induce the formation of a NR2B-
PSD-95-nNOS complex. This complex will trigger production
of NO followed by apoptosis (Christopherson et al., 1999;
Sattler et al., 1999). Therefore, LBP may block the formation
of the NR2B-PSD-95-nNOS complex by inhibiting expression
of NR2B at the time point. At late stages (OGD for 4 h),
however, when expression of NR2B was completely depressed,
LBP did not further inhibit NR2B expression. LBP still prohibited
overexpression of nNOS, which may be mediated through
inhibiting a cascade of events related to mitochondrial injury and
apoptosis, including reduction of calcium influx, mitochondrial
permeability, Bad, cytC and caspase-3 levels after 4 h OGD.
This is consistent with prior finding in an in vivo MCAO
model (Wang T. et al., 2014). Finally, we used a NR2A inhibitor
NVP-AAM077 andNR2B co-agonist D-serine to test whether the
neuroprotective influence of LBP would antagonize the effect of
these two drugs. Our results indicate that LBP can greatly block
the action of NVP-AAM077 and D-serine, which suggests that
LBP imparts its neuroprotective effects through inhibiting NR2B
or activating NR2A.
Interestingly, LBP plays its dual roles in acting as an
antagonist to NR2B while as an agonist to NR2A under
ischemic/hypoxic conditions. This may stem from the presence
of multiple components of LBP with structures composing
of different backbones and branches (Wang et al., 2009; Zou
et al., 2010; Wang Z. et al., 2014; Yuan et al., 2016). These
multiple components, together with other ligands including
glycine and glutamate, may exert complex effects on NMDA
receptors. Furthermore, the different synaptic localization of
NR2A (intrasynaptic)- and NR2B (extrasynaptic)-containing
NMDA receptors may account for the dual roles of LBP as
observed in this study. Therefore, LBP can be the regulator
for both blocking NR2B expression and upregulating NR2A
expression under hypoxic/ischemic conditions. It has also been
reported that, LBP can protect neurons in the optic nerve injury
model by inhibition of JNK pathways and scavenging free radical
(Lin et al., 2009; Li et al., 2013). Thus, LBP exerts neuroprotective
effects through multiple pathways. Further studies are needed
to dissect the exact mechanisms by which LBP exerts under
hypoxic/ischemic conditions.
It should be noted that for our in vitro analyses, we set a
control-LBP group to investigate whether LBP affects neural
viability and expression ofmajor proteins in theNR2B andNR2A
signaling pathways under normal physiological conditions.
Our results indicated that there were no significant changes
by LBP treatment, suggesting that LBP is safe to neuronal
cells. Overall, the present study demonstrated that LBP is
neuroprotective against ischemic injury by its dual roles in
activation of NR2A-mediated survival pathway and inhibition
of NR2B-mediated apoptotic pathway, which suggests that LBP
may be a superior therapeutic candidate for the treatment of
ischemic stroke.
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